Description

Therapeutic vaccination has emerged as one of the most important strategies that can restore T-cell responses and control viral replication without cART. mRNA-based vaccines are among the most promising approaches for the treatment of HIV infections and allow a large-scale production of the vaccine. Given the inherent sensitivity
of RNA to ambient RNases, these approaches will however require protection of mRNA.
So far, therapeutic immunization has been mainly limited to antigen- delivery via systemic routes. However, in many cases the HIV reservoir in the gut is resistant to systemic treatment and the effect on CD4+ T-cells in the lamina propria is different to the periphery. Therefore, a peroral vaccination and immunization is desirable. As mRNA is sensitive to the gastrointestinal environment, it cannot be
applied in a conventional peroral dosage form. By nanoencapsulation of these biomolecules into a nanoparticular carrier system, the
nucleic acid is protected from degradation and accumulates in the Peyer’s patches where they are delivered to lymphoid tissue that is designed to initiate immune response. In this project we will evaluate the feasibility of delivering an mRNA based therapeutic vaccine against HIV using biodegradable nanoparticles loaded with RNA entrapped by a layer-by-layer technique to generate hollow hybrid inorganic-organic containers.
AcronymFWOAL974
StatusActive
Effective start/end date1/01/2031/12/23

    Flemish discipline codes

  • Drug discovery and development not elsewhere classified
  • Vaccinology

ID: 49983734